CN115068435A - Preparation method of nicergoline tablets - Google Patents
Preparation method of nicergoline tablets Download PDFInfo
- Publication number
- CN115068435A CN115068435A CN202210929423.6A CN202210929423A CN115068435A CN 115068435 A CN115068435 A CN 115068435A CN 202210929423 A CN202210929423 A CN 202210929423A CN 115068435 A CN115068435 A CN 115068435A
- Authority
- CN
- China
- Prior art keywords
- nicergoline
- coating
- tablet
- tablets
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method of nicergoline tablets, which comprises anhydrous calcium hydrogen phosphate, microcrystalline cellulose, carboxymethyl starch sodium and magnesium stearate besides nicergoline serving as an active ingredient; the coating solution comprises hydroxypropyl methylcellulose, Arabic gum, talcum powder, titanium dioxide, heavy magnesium carbonate and purified water. The invention adopts the special coating liquid for coating, the coating weight is greatly reduced, the dissolution and release are consistent with those of sugar-coated tablets, the quality of the tablets is the same as that of the original ground products, but the coating weight is less than that of the sugar coating, the cost is greatly saved, in addition, the tablet prepared by the invention also avoids the problem of over-quick disintegration, the dissolution and release of the medicine are layered, and the action time is prolonged.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a preparation method of nicergoline tablets.
Background
Nicergoline (Nicergoline) is a semisynthetic ergoline derivative, has alpha receptor blocking and blood vessel dilating effects, and can enhance metabolism of brain cell energy, increase oxygen and glucose utilization, promote conversion of neurotransmitter dopamine to enhance nerve conduction, enhance brain protein biosynthesis, and improve brain function. The nicergoline tablet is suitable for acute and chronic vascular or metabolic cerebral insufficiency (cerebral arteriosclerosis, cerebral thrombosis and embolism, transient ischemic attack).
The original product preparation of the existing nicergoline tablet is a sugar-coated tablet. The coating mode comprises sugar coating or film coating, and the sugar coating process and equipment are replaced by the coating process of an efficient coating machine. However, both methods have certain defects, for example, if the sugar coating is coated, the weight of the sugar coating can reach the same weight as that of the tablet core, for example, 100mg of sugar coating is required to be coated on 100mg of tablet core; the film coat has the problem of too fast disintegration because the film coat is too thin.
Disclosure of Invention
The invention aims to solve the technical problems in the prior art and provides a preparation method of nicergoline tablets, which adopts special coating liquid to coat by using a high-efficiency coating machine of a modern process, so that the coating weight is greatly reduced, the dissolution and release effects are consistent with those of sugar-coated tablets, and the quality of the nicergoline tablets is the same as that of the original ground products.
In order to realize the purpose, the invention adopts the technical scheme that: a preparation method of nicergoline tablets comprises the following steps:
1) premixing
Preparing raw and auxiliary materials: nicergoline as active ingredient, anhydrous calcium hydrogen phosphate and microcrystalline cellulose as filler, carboxymethyl starch sodium as disintegrant, and magnesium stearate as lubricant;
sieving anhydrous calcium hydrogen phosphate for pretreatment; adding half of anhydrous calcium hydrogen phosphate and half of microcrystalline cellulose into a hopper mixer, and adding nicergoline and sodium carboxymethyl starch into the hopper mixer; finally, adding the remaining anhydrous calcium hydrophosphate and microcrystalline cellulose into a hopper mixer; premixing;
2) sieving
Sieving the premixed material of 1) by using a centrifugal sieving machine, and sieving the magnesium stearate;
3) final mix
Adding the sieved pre-mixed material of 2) into a hopper mixer, adding the sieved magnesium stearate into the hopper mixer, and mixing;
4) tabletting
Pressing the mixed material obtained in the step 3) into plain tablets;
5) coating film
5.1) preparation of stock
Preparing hydroxypropyl methylcellulose as a film forming agent, arabic gum as a binder, talcum powder as an anti-sticking agent, titanium dioxide as an opacifier, heavy magnesium carbonate as a colorant and purified water as a solvent;
sieving talcum powder, titanium dioxide and heavy magnesium carbonate;
5.2) preparation of coating solution
Weighing purified water, adding into a stirrer, and stirring until vortex is formed; firstly, adding hydroxypropyl methylcellulose into the vortex, and then adding Arabic gum; stirring until the solution is completely dissolved, and slowly stirring or standing for defoaming to obtain a liquid 1;
weighing purified water into a container, slowly adding sieved talcum powder, titanium dioxide and heavy magnesium carbonate, and homogenizing by using an emulsifying machine to obtain liquid 2;
combining the liquid 1 and the liquid 2, washing the container with purified water, transferring the liquid as completely as possible, and continuously stirring to obtain a coating liquid;
5.3) coating
Putting the plain tablets obtained in the step 4) into a tablet bed, coating and spraying liquid by using the coating liquid, stopping spraying the liquid when the weight of the plain tablets is increased by 12.5 +/-0.5 percent, namely the weight of the target coating is 12.5 +/-0.5 percent of the weight of the plain tablets, drying, and cooling to room temperature.
Wherein, the anhydrous calcium hydrogen phosphate sieving in the step 1) is to sieve the anhydrous calcium hydrogen phosphate through a 30-mesh sieve by using a vibrating sieve.
Wherein, the magnesium stearate sieving in the step 2) is to pass through a 30-mesh sieve.
Wherein, the tabletting of the step 4) is a plain tablet pressed into a 6.0mm round punch.
In the step 5.1), the talcum powder, the titanium dioxide and the heavy magnesium carbonate are sieved by a 30-mesh sieve.
In the step 5.3), the tablet bed is preheated to 40-45 ℃ to start coating and spraying, the temperature of the tablet bed is controlled to be 40-50 ℃ in the coating process, and the flow rate of the spraying liquid is 10-150 g/min/gun.
Wherein the tablet core weight of each nicergoline tablet is 65mg/130mg, and each tablet core contains 5mg/10mg of nicergoline, 20-105mg of anhydrous calcium hydrogen phosphate, 5-105mg of microcrystalline cellulose, 0.1-5mg of carboxymethyl starch sodium and 0.1-5mg of magnesium stearate.
Wherein the tablet core weight of each nicergoline tablet is 130mg, and each tablet core contains nicergoline 10mg, anhydrous calcium hydrogen phosphate 77mg, microcrystalline cellulose 40mg, carboxymethyl starch sodium 1mg, and magnesium stearate 2 mg.
Wherein, the coating material of each nicergoline tablet contains 1-10mg of hypromellose, 0.5-3mg of Arabic gum, 1-10mg of talcum powder, 0.1-1mg of titanium dioxide and 0.1-1mg of heavy magnesium carbonate.
Wherein, the coating material of each nicergoline tablet contains 8mg of hypromellose, 1.25mg of Arabic gum, 6mg of talcum powder, 0.5mg of titanium dioxide and 0.5mg of heavy magnesium carbonate.
The invention has the beneficial effects that: most of the original grinding products of the nicergoline tablets are sugar-coated tablets, the weight ratio of sugar coating is very high, the invention adopts special coating liquid and uses a high-efficiency coating machine for coating, the coating weight is only about 12% of the weight of the tablet cores, the dissolution and release effects are consistent with those of the sugar-coated tablets, the quality of the product is the same as that of the original grinding product, but the coating weight is less than the sugar coating, the cost is greatly saved, in addition, the problem of over-quick disintegration is avoided for the tablets prepared by the invention, the dissolution and release of the medicine are layered, and the action time is prolonged.
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes or modifications can be made by those skilled in the art after reading the disclosure of the present invention, and such equivalents also fall within the scope of the invention.
Example 1:
table 1 shows the amounts of the ingredients used to prepare nicergoline tablets (10000 tablets).
TABLE 1
1) Premixing
Preparing raw and auxiliary materials: nicergoline as active ingredient, anhydrous calcium hydrogen phosphate and microcrystalline cellulose as filler, carboxymethyl starch sodium as disintegrant, and magnesium stearate as lubricant;
pretreating anhydrous calcium hydrogen phosphate by sieving with a 30-mesh sieve by using a vibrating sieve; adding half of anhydrous calcium hydrogen phosphate and half of microcrystalline cellulose into a hopper mixer, and adding nicergoline and sodium carboxymethyl starch into the hopper mixer; finally, adding the residual anhydrous calcium hydrophosphate and microcrystalline cellulose into a hopper mixer for premixing;
2 sieving
Sieving the premixed material by using a centrifugal sieving machine, and sieving magnesium stearate by using a 30-mesh sieve;
3 Final mixing
Adding the sieved pre-mixed materials into a hopper mixer, and adding the sieved magnesium stearate into the hopper mixer for mixing;
4. tabletting
Pressing the mixed material into 6.0mm round punched plain sheets;
5. coating
5.1 preparation of materials
Preparing hydroxypropyl methylcellulose as a film forming agent, arabic gum as a binder, talcum powder as an anti-sticking agent, titanium dioxide as an opacifier, heavy magnesium carbonate as a colorant and purified water as a solvent;
sieving talcum powder, titanium dioxide and heavy magnesium carbonate with 30 mesh sieve;
5.2 preparation of coating solution
Weighing purified water, adding into a stirrer, and stirring until vortex is formed; firstly, adding hydroxypropyl methylcellulose into the vortex, and then adding Arabic gum; stirring until the solution is completely dissolved, and slowly stirring or standing for defoaming;
weighing part of purified water into a stainless steel barrel, slowly adding sieved talcum powder, titanium dioxide and heavy magnesium carbonate, and homogenizing by using an emulsifying machine;
combining the two parts of liquid, and rinsing a stainless steel barrel by using 4.0kg of purified water, and transferring the liquid as completely as possible; continuously stirring to obtain a coating solution;
5.3. coating film
Preheating the tablet bed to 40-45 deg.C, coating and spraying liquid to the tablet, controlling the temperature of the tablet bed to 40-50 deg.C, and the flow rate of the liquid spray to 10-150 g/min/gun, stopping spraying liquid when the coating weight is 12.5 + -0.5% of the weight of the tablet, drying for 20min, and cooling to room temperature.
Example 2: dissolution Performance test
The results of comparing the dissolution curves of the prepared nicergoline tablet formulation with the reference formulation and the prior art formulation are shown in table 2. The preparation of the nicergoline tablet imitation (specification: 10mg, batch number: NIT200801, NIT200804 and NIT200805) and the reference preparation (SERMION, specification: 10mg, batch number: DA1582) of the invention are compared with the average dissolution amount (n is 12) of the prior art preparations (specification: 10mg, batch number: NIT200601, NIT200602 and NIT200603) under the dissolution medium of 0.1mol/L hydrochloric acid solution. As can be seen from Table 2, the in vitro dissolution behavior of each batch of the preparation prepared by the invention is consistent with that of the reference preparation, and the quality of the preparation is the same as that of the original product.
The invention adopts special coating liquid and uses high-efficiency coating machine to coat, the dissolving release is consistent with the sugar-coated tablet, the quality is the same as the quality of the original ground product, but the coating weight is less than the sugar coating, the cost is greatly saved, in addition, the tablet prepared by the invention also avoids the problem of over-quick disintegration, the medicine dissolving release has hierarchy, and the action time is increased.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention, including any reference to the above-mentioned embodiments. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. A preparation method of nicergoline tablets is characterized by comprising the following steps:
1) premixing
Preparing raw and auxiliary materials: nicergoline as active ingredient, anhydrous calcium hydrogen phosphate and microcrystalline cellulose as filler, carboxymethyl starch sodium as disintegrant, and magnesium stearate as lubricant;
sieving anhydrous calcium hydrogen phosphate for pretreatment; adding half of anhydrous calcium hydrogen phosphate and half of microcrystalline cellulose into a hopper mixer, and adding the nicergoline raw material and the carboxymethyl starch sodium into the hopper mixer; finally, adding the remaining anhydrous calcium hydrophosphate and microcrystalline cellulose into a hopper mixer; premixing;
2) sieving
Sieving the premixed material of 1) by using a centrifugal sieving machine, and sieving the magnesium stearate;
3) final mix
Adding the sieved pre-mixed material of 2) into a hopper mixer, adding the sieved magnesium stearate into the hopper mixer, and mixing;
4) tabletting
Pressing the mixed material obtained in the step 3) into plain tablets;
5) coating film
5.1) preparation of stock
Preparing hydroxypropyl methylcellulose as a film forming agent, arabic gum as a binder, talcum powder as an anti-sticking agent, titanium dioxide as an opacifier, heavy magnesium carbonate as a colorant and purified water as a solvent;
sieving talcum powder, titanium dioxide and heavy magnesium carbonate respectively;
5.2) preparation of coating solution
Weighing purified water into a stirrer, and stirring until vortex is formed; firstly, adding hydroxypropyl methylcellulose into the vortex, and then adding Arabic gum; stirring until the solution is completely dissolved, and slowly stirring or standing for defoaming to obtain a liquid 1;
weighing purified water into a container, adding sieved talcum powder, titanium dioxide and heavy magnesium carbonate, and homogenizing to obtain liquid 2;
mixing the liquid 1 and the liquid 2, and continuously stirring to obtain a coating solution;
5.3) coating
Placing the plain tablets obtained in the step 4) in a tablet bed, coating and spraying liquid by using the coating liquid obtained in the step 5.2), stopping spraying liquid when the weight of the plain tablets is increased by 12.5 +/-0.5 percent, namely the weight of the target coating is 12.5 +/-0.5 percent of the weight of the plain tablets, drying, and cooling to room temperature.
2. The method for preparing nicergoline tablets as claimed in claim 1, wherein the anhydrous calcium hydrogen phosphate of step 1) is sieved with a vibrating sieve through a 30-mesh sieve.
3. The method for preparing nicergoline tablets according to claim 1, wherein the sieving of magnesium stearate in step 2) is a 30-mesh sieve.
4. The method for preparing nicergoline tablets according to claim 1, wherein the compressed tablet of step 4) is a plain tablet pressed into a 6.0mm round punch.
5. The method for preparing nicergoline tablet according to claim 1, wherein in the step 5.1), talcum powder, titanium dioxide and heavy magnesium carbonate are sieved by a 30-mesh sieve.
6. The method for preparing nicergoline tablets according to claim 1, wherein in step 5.3), the tablet bed is preheated to 40-45 ℃ to start coating with spray, and the temperature of the tablet bed is controlled to be 40-50 ℃ during coating, and the flow rate of the spray is controlled to be 10-150 g/min/gun.
7. The preparation method of nicergoline tablet according to claim 1, wherein the tablet core weight of each nicergoline tablet is 65mg/130mg, and each tablet core contains 5mg/10mg of nicergoline, 20-105mg of anhydrous calcium hydrogen phosphate, 5-105mg of microcrystalline cellulose, 0.1-5mg of carboxymethyl starch sodium and 0.1-5mg of magnesium stearate.
8. The method for preparing nicergoline tablets according to claim 7, wherein the tablet core weight of each nicergoline tablet is 130mg, and each tablet core contains nicergoline 10mg, anhydrous calcium hydrogen phosphate 77mg, microcrystalline cellulose 40mg, carboxymethyl starch sodium 1mg and magnesium stearate 2 mg.
9. The method for preparing nicergoline tablets according to claim 1, wherein a coating material of each nicergoline tablet contains 1-10mg of hypromellose, 0.5-3mg of acacia gum, 1-10mg of talcum powder, 0.1-1mg of titanium dioxide and 0.1-1mg of heavy magnesium carbonate.
10. The method for preparing nicergoline tablets according to claim 9, wherein the coating material of each nicergoline tablet contains 8mg of hypromellose, 1.25mg of acacia, 6mg of talcum powder, 0.5mg of titanium dioxide and 0.5mg of heavy magnesium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210929423.6A CN115068435B (en) | 2022-08-03 | 2022-08-03 | Preparation method of nicergoline tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210929423.6A CN115068435B (en) | 2022-08-03 | 2022-08-03 | Preparation method of nicergoline tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115068435A true CN115068435A (en) | 2022-09-20 |
| CN115068435B CN115068435B (en) | 2023-04-25 |
Family
ID=83242115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210929423.6A Active CN115068435B (en) | 2022-08-03 | 2022-08-03 | Preparation method of nicergoline tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068435B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536508A (en) * | 1990-11-22 | 1996-07-16 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
| JP2001354566A (en) * | 2000-06-16 | 2001-12-25 | Ohara Yakuhin Kogyo Kk | Tablet of nicergoline |
| CN102949372A (en) * | 2011-08-26 | 2013-03-06 | 山东方明药业集团股份有限公司 | Nicergoline pill and preparation method thereof |
| US20140335153A1 (en) * | 2013-05-09 | 2014-11-13 | Cure Pharmaceutical Corporation | Thin film with high load of active ingredient |
| CN110051639A (en) * | 2019-03-15 | 2019-07-26 | 河北嘉迈医药科技有限公司 | A kind of fater disintegration type nicergoline tablets and preparation method thereof |
| CN111904938A (en) * | 2020-05-15 | 2020-11-10 | 山东方明药业集团股份有限公司 | Preparation method of nicergoline tablets |
-
2022
- 2022-08-03 CN CN202210929423.6A patent/CN115068435B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536508A (en) * | 1990-11-22 | 1996-07-16 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
| JP2001354566A (en) * | 2000-06-16 | 2001-12-25 | Ohara Yakuhin Kogyo Kk | Tablet of nicergoline |
| CN102949372A (en) * | 2011-08-26 | 2013-03-06 | 山东方明药业集团股份有限公司 | Nicergoline pill and preparation method thereof |
| US20140335153A1 (en) * | 2013-05-09 | 2014-11-13 | Cure Pharmaceutical Corporation | Thin film with high load of active ingredient |
| CN110051639A (en) * | 2019-03-15 | 2019-07-26 | 河北嘉迈医药科技有限公司 | A kind of fater disintegration type nicergoline tablets and preparation method thereof |
| CN111904938A (en) * | 2020-05-15 | 2020-11-10 | 山东方明药业集团股份有限公司 | Preparation method of nicergoline tablets |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115068435B (en) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2453306C2 (en) | Solid oral dosage forms of valsartan | |
| EP1135106B1 (en) | Sustained release matrix systems for highly soluble drugs | |
| JP7551182B2 (en) | Composition for oral sustained release of poorly soluble drugs and method for preparing same | |
| CN112494440B (en) | Sitagliptin phosphate tablet and preparation method thereof | |
| CN109464415B (en) | Apixaban pharmaceutical composition and preparation method thereof | |
| CN115068435B (en) | Preparation method of nicergoline tablet | |
| CN115590833A (en) | Lercanidipine hydrochloride tablet composition with high dissolution stability and preparation method thereof | |
| CN101711753B (en) | Preparation method of lansoprazole solid preparation | |
| CN110430871A (en) | The pharmaceutical composition of pirfenidone of grain-size controlled and preparation method thereof that compressibility improves | |
| CN108096207B (en) | Preparation method of lotafloxacin enteric-coated tablets | |
| CN108853044B (en) | Nifedipine sustained release tablet and preparation method thereof | |
| CN107744509B (en) | Mosapride citrate tablet and preparation method thereof | |
| CN107582528B (en) | Method and products thereof for wet granulation | |
| CN110693884A (en) | Compound preparation valsartan amlodipine tablet and preparation method thereof | |
| CN104013971B (en) | A kind of bromocriptine composition sustained-release preparation and preparation method thereof | |
| CN106491550B (en) | Sustained-release tablet containing quetiapine or pharmaceutically acceptable salt thereof and preparation method thereof | |
| CN107823163A (en) | A kind of Etoricoxib tablet composition | |
| CN113521022B (en) | Sustained-release tablet containing alexidine and preparation method thereof | |
| CN118415996A (en) | Dapagliflozin quick-release tablet and preparation method thereof | |
| CN113041227A (en) | Apixaban tablet and preparation method thereof | |
| CN113018270A (en) | High-stability milnacipran hydrochloride preparation and preparation method thereof | |
| CN117281787A (en) | Metformin hydrochloride sustained release tablet and preparation method thereof | |
| CN115887399A (en) | Selipacard tablet and preparation method thereof | |
| CN108324696B (en) | Indapamide-containing tablet and preparation method thereof | |
| CA2030870A1 (en) | Pressing not delayed release of active compound, process for its production and use of polyhydroxybutyric acid for the production of such a pressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |